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Few tissue markers are currently available to pathologists in the study of hepatocellular 
tumors. These markers should be used carefully taking into consideration not only 
morphology but also, and sometimes even more important, the clinical setting where 
the lesion to be diagnosed had developed. Glypican-3, heat shock protein 70, and 
glutamine synthetase (GS) are markers currently used, as a single panel, to discriminate 
the nature of a <2 cm hepatocellular lesion lacking radiological features of hepatocellular 
carcinoma (HCC) detected in a cirrhotic patient under surveillance. Their use, which can 
be improved by clathrin heavy chain, is mostly requested on liver biopsy. Hepatocyte 
paraffin 1, arginase-1, polyclonal carcinoembryonic antigen, CD10, and bile salt export 
pump are tissue markers used to confirm, at histology, the diagnosis of HCC made by 
imaging before enrollment for phase III studies on novel anti-HCC drugs. In this setting, 
pathologists are usually requested a conclusive diagnosis on a liver biopsy of a poorly 
differentiated, necrotic, enriched in stem-phenotype, carcinoma. Liver fatty acid-binding 
protein, serum amyloid A, C-reactive protein, prostaglandin D2 synthetase, GS, and 
β-catenin can be used either on biopsy or surgical specimen to classify hepatocellular 
adenoma into hepatocyte nuclear factor (HNF-1α) inactivated (steatotic), inflammatory, 
with dysregulation of sonic hedgehog and prostaglandin pathways, β-catenin mutated, 
and unclassified.
Keywords: hepatocellular tumors, hepatocellular carcinoma, hepatocellular adenoma, tissue markers, predictive 
markers, prognostic markers
iNTRODUCTiON
Immunohistochemistry is often defined as ancillary to morphology. Coming from the latin 
ancilla, servant, the term ancillary indicates something servant or subordinate, suggesting that 
immunohistochemistry should be regarded as subordinate to morphology. In other words, it is 
morphology that should dictate the use of immunohistochemistry. This is even more stringent in 
the study of hepatocellular tumors where the use of tissue biomarkers is subordinate not only to 
morphology but also to the clinical requests. In the daily practice, these latter are mainly restricted 
to the followings:
(1) histopathological diagnosis of a <2 cm hepatocellular lesion lacking radiological features of 
hepatocellular carcinoma (HCC) detected in a cirrhotic patient under surveillance; material: 
biopsy specimen; differential diagnosis: dysplastic nodules (DNs) versus HCC;
(2) histopathological diagnosis of HCC in patients with a radiological diagnosis of HCC, developed 
in a contest of cirrhosis, who already experienced all available treatments, to be enrolled for 
phase III studies on novel anti-HCC drugs; material: biopsy specimen; differential diagnosis: 
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HCC, intrahepatic cholangiocarcinoma (iCC); mixed hepa-
tocholangiocellular carcinoma; metastases (rare);
(3) histopathological diagnosis in a hepatocellular lesion(s) 
discovered in not cirrhotic liver of a patient without onco-
logical diseases; material: biopsy (frequent in the present; 
less probably in the future) and surgical specimen; differ-
ential diagnosis: focal nodular hyperplasia (FNH) versus 
hepatocellular adenoma (HA).
In the following paragraphs, we will discuss in detail the 
advantages and pitfalls of biomarkers used in each of these specific 
clinic-pathological settings, adding some practical considerations 
related to personal experience.
SMALL HePATOCeLLULAR NODULe iN A 
CiRRHOTiC PATieNT
Due to radiological surveillance of cirrhotic patients, a growing 
number of hepatocellular nodules <2 cm are recognized: 30–40% 
of them are diagnosed as HCC using imaging, the remaining 
require histopathological diagnosis. In this setting, whose clini-
cal, radiological, and pathological features have been described 
in detail elsewhere (1), a panel of biomarkers has been proposed, 
validated, and it is currently considered a recommended diag-
nostic tool. It includes glypican-3 (GPC3), heat shock protein 70 
(HSP70), and glutamine synthetase (GS).
Glypican-3
Glypican-3 is a membrane-anchored heparin sulfate proteogly-
can normally expressed in fetal liver and placenta, but not in 
normal adult liver. Hsu et al. (2) first reported that GPC3 mRNA 
levels were significantly higher in HCC as compared to normal 
liver and non-malignant liver lesions, a result later confirmed 
also at protein level (3). In particular, when investigated in biopsy 
material, up to 60% of G1/early HCC shows immunoreactivity 
to GPC3, either as membrane and/or cytoplasmic staining, as 
well as 8% of high-grade DN (4) and occasional cirrhotic frag-
ments (5); figures to be compared to the 85% staining observed 
in G2–G3 HCC.
Once excluded, the possibility of immunoreactive cirrhotic 
cells (usually very few or isolated in a background of a parenchyma 
lacking architectural atypia), a positive GPC3 staining supports a 
diagnosis of HGDN or early/G1 HCC. To distinguish these two 
lesions, staying close at the border of malignancy, GPC3-positive 
cells should then be quantified. Data from surgical specimen 
showed that 3/4 of early/G1 HCC have >10% GPC3-positive cells: 
if immunoreactive cells observed in the lesional biopsy largely 
outnumber this amount, a putative diagnosis of malignancy can 
be considered, pending the results of HSP70 and GS. Indeed, as 
will be discussed at the end of this section, the presence of a single 
marker positive staining will be boosted up by positive results of 
the other two of the panel.
Heat Shock Protein 70
Heat shock protein 70 is an antiapoptotic protein whose over-
expression allows cell survival. Chuma et  al. (6), working in a 
subset of hepatocellular lesions with a nodule in nodule pattern 
of growth (outer: HGDN; inner: early HCC), showed that in the 
inner part HSP70 was the most abundantly upregulated gene. 
These results were robustly confirmed when HSP70 was tested 
at tissue level in surgical specimen where only 1/22 (4%) HGDN 
as compared to 25/32 (78%) early/G1 HCC showed a positive 
nucleocytoplasmic staining (7). However, when the marker was 
tested on liver biopsy, while retaining a 90% specificity the sensi-
tivity decreases to 61% (4), possibly due to low immunoreactivity 
of archive material.
The key point in the daily use of HSP70 mainly rests in the 
recognition and proper interpretation of positive cells. Lesional 
elements are usually arranged in small cluster or in pseudoacini 
and should be distinguished from cords of apoptotic hepatocytes, 
isolated periseptal hepatocytes, and some stellate cells, which can 
be immunoreactive for HSP70.
Glutamine Synthetase
Glutamine synthetase (GS) is an enzyme of nitrogen metabolism 
and catalyzes the conversion of glutamate and ammonia to 
glutamine in the liver. In normal liver, GS is expressed by one 
or two hepatic plates around central vein. GS is also a target of 
β-catenin and is upregulated when this pathway is activated. 
Many liver nodules, benign or malignant, show a GS overexpres-
sion: the pattern of the immunostaining (diffuse/patchy/focal, 
homogenous/not homogenous, strong/faint) should be evaluated 
carefully and interpreted according to the clinical contest to avoid 
misdiagnosis.
In our original study on the use of GS in the diagnosis of small 
hepatocellular nodules in a cirrhotic background (7), we reported 
a sensitivity of 69% and a specificity of 94% for a homogeneous and 
intense pattern of staining. We also described a heterogeneous or 
faint staining in six cases of HGDN, which, from a practical point 
of view were considered as negative. More recently, Rebouissou 
et al. (8) showed that diffuse, homogeneous, and strong immuno-
reactivity to GS (usually coupled with nuclear immunoreactivity 
to β-catenin) is always related to “high-activity” β-catenin muta-
tions, while a faint or weak/heterogeneous staining is related to 
“weak activity” mutations. The latter characterized benign HA at 
low risk of malignant transformation; the former was typically 
observed in overt HCC as well as in lesions with borderline 
features between HA and HCC.
In the liver biopsy, we suggested to consider as GS positive 
only those lesions showing >50% strong immunoreactivity (4) 
and to evaluate the results together with those of GPC3 and 
HSP70. The study by Rebouissou et al. (8) prompts a step forward: 
to consider, when discovered in cirrhotic patients, as suspicious 
for HCC all lesions with strong and diffuse GS staining. We also 
suggested to consider carefully a faint GS staining when observed 
in liver biopsy (4): the paper of Rebouissou et al. (8) support the 
hypothesis that these cases harbor a “weak-activity” mutation of 
β-catenin with a different impact on nodule’s fate (lower risk of 
transformation).
Combined Use of Markers
A positive immunostaining to GPC3, HSP70, or GS may be useful 
or suggestive for a diagnosis of HCC but, taken alone, perhaps 
with the exception of strong/diffuse GS, none of these positive 
FiGURe 1 | Morphological and immunohistochemical features of a 1.7 cm hepatocellular lesion detected in a cirrhotic patient with imaging not 
conclusive for malignancy. (A) The lesion is barely seen on the left of the biopsy (H/E, 4×); (B) at higher magnification, it is characterized by cell crowding and not 
triadal vessels (H/E, 40×); and (C) rare pseudoglands (H/E, 40×). Overall, morphological features are in keeping with a differential diagnosis between HGDN and 
early/G1 hepatocellular carcinoma (HCC). The lesion, when investigated with the diagnostic panel glypican-3 (GPC3)–heat shock protein 70 (HSP70)–glutamine 
synthetase (GS) showed (D) a strong GS staining in patchy areas (GS staining, 4×), (e) a focal cytoplasmic staining for GPC3 (GPC3 staining, 40×), and (F) the 
presence of scattered lesional cells arranged in cluster showing nuclear/cytoplasmic immunoreactivity for HSP70 (HSP70 immunostaining, 40×). All these findings 
are in keeping with a conclusive diagnosis of early/G1 HCC.
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results are conclusive. By contrast, the combined use of them 
warrants 100% specificity and 72% of sensitivity. Accordingly, 
international guidelines recommend the combined use of them 
(9) and, in our daily experience, we always face the clinical request 
DN versus G1/early HCC using this “panel,” i.e., using more than 
a single marker, approach.
Some other makers have been proposed as useful in the diag-
nosis of hepatocellular nodule arising in the setting of a cirrhosis: 
among these, clathrin heavy chain (CHC) and EZH2 were those 
showing better results (10, 11). In our experience, CHC is easier 
to be evaluated on liver biopsy due to the fact that cytoplasmic 
immunoreactivity is observed, if present, only in lesional hepato-
cytes. Moreover, it reveals high specificity and, most important, 
high sensitivity: it is part of an enlarged panel represented by 
GPC3, HSP70, GS, and CHC we use in the diagnostic of <2 cm 
hepatocellular nodules discovered in cirrhotic surveillance. 
Figure  1 shows a typical example of a very well-differentiated 
hepatocellular lesion and the results of markers.
FiRST HiSTOPATHOLOGiCAL DiAGNOSiS 
(AFTeR MANY TReATMeNTS FOR HCC)
According to current guidelines, the great majority of “bona 
fide” HCC are diagnosed according to radiological criteria, 
without any histological diagnosis, and treated in line with 
clinical criteria (9). Many of these patients experienced a liver 
biopsy aimed to obtain a histopathological diagnosis of HCC 
after many treatments (surgical, ablative, and medical) usually 
before enrollment in phase III clinical studies on new drug. 
These cases, due to their natural history and treatment as well, 
are poorly differentiated, partially necrotic, or even shifted 
toward a stem differentiation and a final diagnosis can be ren-
dered only with the support of tissue markers. Those currently 
used are hepatocyte paraffin 1 (HepPar-1), arginase-1, CD10, 
polyclonal carcinoembryonic antigen (pCEA), GPC3, and bile 
salt export pump (BSEP).
Hepatocyte Paraffin 1
Hepatocyte paraffin 1 is an antibody to carbamoyl phosphate syn-
thetase 1, a urea cycle enzyme of mitochondria, predominantly 
expressed in liver and also in other organs (12). It usually shows 
a strong, granular, cytoplasmic immunoreactivity in normal liver, 
hepatoblastoma, and HCC cells. HepPar-1 has 70–84% overall 
sensitivity for the diagnosis of HCC, a value rising to 90% in G1 
HCC; this value, however, may decrease to 20% in G3 HCC (13, 
14). In addition, despite a reported overall specificity of 84%, low 
rates of weak positive staining have been described in gastric, 
lung, small intestinal, colonic, and pancreatic adenocarcinoma, 
as well as in melanoma, cholangiocarcinoma, ovarian, and 
neuroendocrine carcinoma; finally, HepPar-1 marks all tumors 
with hepatoid features (15). Taking into consideration all these 
caveats, HepPar-1, if used alone, plays a minor role in histotyping 
a poorly differentiated carcinoma presenting in the liver. Only 
cases showing strong and diffuse staining can be considered as 
bona fide HCC (14). By contrast, a faint positive staining, rather 
than helpful may, paradoxically, be an element of confusion sup-
porting a diagnosis of HCC, which the use of a larger panel would 
have rule out.
TABLe 1 | Sensitivity of markers used to prove hepatocellular carcinoma 
(HCC) nature of a liver lesion.




Hepatocyte paraffin 1 70–84 22–78
Arginase 84–96 44–89
Polyclonal carcinoembryonic antigen 45–81 78
CD10 50–74 67
Glypican-3 54 67
Bile salt export pump 90 78
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Arginase-1
Arginase isoforms 1 and 2 are involved in the hydrolysis of 
arginine to ornithine and urea in the urea cycle. The isoform 1 is 
highly expressed in the liver, while isoform 2 is expressed in the 
kidney and in a lesser extent in the liver. Arginase-1 is expressed 
at cytoplasmic and/or nuclear level. The overall sensitivity of 
arginase-1 in the diagnosis of HCC ranges between 84 and 96% 
(13, 14); in addition, even if the expression decreases as HCC 
grade increases, in G3 HCC sensitivity still remains between 44 
and 89%, with a reported value of 54% in cases showing strong 
and diffuse positivity (14). The expression of arginase-1 has 
been reported in few cases of colon, gastric, lung, and pancreatic 
cancers, with a specificity for the diagnosis of HCC of 96% (13). 
Accordingly, the histotyping of poorly differentiated lesions 
of the liver may benefit of the use of arginase-1, even as single 
marker.
pCeA and CD10
Polyclonal carcinoembryonic antigen stains a biliary glycopro-
tein similar to CEA expressed by the bile canaliculi and ducts. 
pCEA shows a peculiar pattern of staining in normal hepatocytes 
represented by a faint, spider-like, reaction in the canalicular 
pole of the hepatocyte; this so-called “canalicular pattern” is 
extremely characteristic and highly specific for HCC. Only few 
cells of HCC, in rare cases, may show a cytoplasmic staining; 
this latter, by contrast, is typical of metastatic adenocarcinoma 
and iCC.
CD10 is a membrane metalloendopeptidase, which cuts the 
amino group of hydrophopic residues. It is normally expressed 
in cytoplasm/membrane of many adenocarcinomas, while in 
normal hepatocytes and HCC, it shows the same “canalicular 
pattern” observed with pCEA. Despite an almost 100% specific-
ity, the “canalicular pattern” is affected by a low sensitivity for 
both pCEA (45–81%) and CD10 (50–74%); interestingly enough, 
these values rise up to 78 and 67%, respectively, in G3 HCC.
Glypican-3
Glypican-3 expression has been reported in melanomas, extrago-
nadal germ cell tumors, squamous cell carcinoma of the lung, 
squamous- and adenocarcinoma of the esophagum, ovarian 
tumor, and, most important, in up to 14% of GI and pancreatic 
liver metastasis (6), with an overall specificity for HCC of 86% 
(16). Thus, despite GPC3 has an 89% sensitivity (16) for G2–G3 
HCC, the use of GPC3 alone to establish the exact histogenesis of 
a liver tumor should be evaluated carefully.
Bile Salt export Pump
Bile salt export pump is an ATP-binding cassette transporter 
expressed almost exclusively in the canalicular part of hepatocytes. 
In a recent study, Lagana et al. (17) investigated the efficiency of 
BSEP to identify HCC against all the other markers mentioned 
above. BSEP showed a convincing canalicular staining in 76% of 
cases and cytoplasmic/dot in the remaining. BSEP, CD10, and 
pCEA showed 100% specificity as compared to 97% of GPC3 and 
HepPar-1 and 94% of arginase. BSEP and arginase showed the 
highest sensitivity (90%), a value progressively decreasing with 
HepPar-1 (90%), pCEA (81%), CD10 (74%), and GPC3 (54%).
Table  1 illustrates the performances of the each of these 
histotype markers when used alone. It should be observed that 
only Radwan and Ahmed (13) investigated the performance of 
two of these markers in combination (arginase and HepPar-1) 
and reported 100% specificity coupled with 70% sensitivity. 
According to our experience with biomarkers, this “panel” 
approach warrants optimal results and should be encouraged 
also in this field.
AN HePATOCeLLULAR NODULe iN 
OTHeRwiSe UNReMARKABLe LiveR
The detection of a, usually single, liver lesion, in a patient 
without known oncological disease and cirrhosis, restricts 
the differential diagnosis to two hepatocellular lesions: FNH 
and HA. Translational studies, mainly coming from a French 
network of researchers, recently defined a robust classifica-
tion of HA with strict correlation between molecular features, 
morphology, clinical aspects, and imaging (18–21). In addition, 
these studies provided to the pathologists a number of tissue 
markers, namely, liver fatty acid-binding protein (LFABP), 
serum amyloid A (SAA), PCR, as well as GS and β-catenin, 
and more recently PTGDS (21), which allows to recognize these 
lesions on tissue specimen. The latter can be represented by 
a liver biopsy, a frequent event in the current daily practice; 
recent EASL guidelines (22) however did not contemplate 
the possibility of a biopsy in the flowchart of HA (which is 
included by contrast in the diagnosis of FNH), thus possibly 
restricting the use of these markers to surgical specimen. A 
detailed, pathology oriented, review of these lesions has been 
reported elsewhere (23).
Liver Fatty Acid-Binding Protein
Liver fatty acid-binding protein is downregulated in HNF-1α 
inactivated HA. The latter are characterized by a steatotic mor-
phology, hence the common name of steatotic HA (s-HA). HNF-
1α inactivated HA are usually easily recognized at imaging (22) 
and has a low potential of malignant transformation; in the rare 
cases where an histopathological diagnosis is requested, it rests 
in the identification of a steatotic nodule with negative LFABP 
staining merging into an otherwise normal parenchyma with a 
positive cytoplasmic LFABP staining. Recently, Cho et  al. (24) 
reported that a negative LFABP can also be observed in HCC; 
thus, a negative staining without adequate morphology is not 
diagnostic per se of an s-HA.
FiGURe 2 | Morpho-phenotypical correlations in the hepatocellular adenomas (HAs). (A,D) This hepatocellular lesion [(A), H/E, 4×, right part of the biopsy] is 
negative to liver fatty acid-binding protein (LFABP) staining [(D), LFABP staining, 4×] findings consistent with a final diagnosis of HNF-1α inactivated, steatotic, HA; 
LFABP cytoplasmic positivity is always observed in normal parenchyma. (B,e) This hepatocellular lesion characterized by ectatic sinusoids [(B), H/E, 10×] shows 
diffuse cytoplasmic immunoreactivity to serum amyloid A (SAA) [(e), SAA immunostaining, 10×], which is diagnostic for an inflammatory (telangiectatic) HA. (C,F) The 
lesional biopsy [(C), H/E, 4×, upper fragment] obtained from a 3 cm hepatcellular nodule in an 18-year-old man shows a strong and diffuse immunoreactivity to 
glutamine synthetase (GS); this finding is consistent with a diagnosis of an atypical (β-catenin mutated) adenoma that was further confirmed by nuclear 
immunoreactivity to β-catenin not shown; note for comparison in the lower fragment the normal GS staining in the perivenular areas.
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SAA/C-Reactive Protein (CRP)
Serum amyloid A associated protein and CRP are upregulated 
in inflammatory HA (i-HA) as a result of activating mutation 
along JAK–STAT pathway. SAA is expressed at cytoplasmic 
level by lesional hepatocytes as well as in some hepatocytes 
surrounding any liver mass and in FNH. PCR shows a similar 
strong, cytoplasmic staining in lesional hepatocytes, coupled 
with a larger amount of patchy immunoreactivity in non-
lesional cells. The combined use of SAA and CPR avoid false 
positive results.
Glutamine Synthetase
HNF-1α inactivated HA, unclassified HA (HA, nos), and 
most i-HA are negative to GS staining; a faint/focal immu-
noreactivity to GS is observed in exon 7/8 β-catenin mutated 
HA (β-HA); a strong/diffuse positivity is observed in exon 
3 β-catenin mutated HA (8). A strong immunoreactivity, 
however, is observed also in FNH: in this lesion, however, 
the immunoreactivity is not diffuse rather “map-like,” the 
latter describing the presence of large, anastomosing group 
of positive hepatocytes, surrounding vessels, and sparring the 
hepatocytes close to fibrotic bands.
In the setting of a liver biopsy obtained from a hepatocel-
lular nodule in unremarkable liver, GS can be extremely useful 
to pathologists. Thus, a lesion characterized by the presence of 
fibrous tissue, suggestive but not conclusive for FNH on H/E, 
can be diagnosed easily if showing a “map-like” GS staining; 
the worrisome findings of hepatocytes with increased N/C ratio 
arranged in acinar structure can be better set as an atypical HA if 
supported by a diffuse/strong GS staining. Figure 2 shows some 
examples of LFABP, SAA, and GS staining in different varieties 
of HA.
Finally, it should be observed that some HAs merge into 
extremely well-differentiated HCC. In these lesions, the dif-
ferential diagnosis between a benign and a malignant lesion can 
be extremely difficult especially on liver biopsy. From a practical 
point of view, two different approaches have been suggested to 
these lesions. Bedossa et  al. (25) suggested to consider these 
lesions as of uncertain malignant potential while Nguyen et al. 
(26) prompted to use HSP70 and GS to distinguish HCC from 
atypical HA. An algorithmic approach to the use of tissue mark-
ers in the diagnosis of hepatocellular nodule in a cirrhotic or 
unremarkable liver, is proposed in Figure 3.
PROGNOSTiC AND PReDiCTive TiSSUe 
BiOMARKeRS: wHeRe ARe we GOiNG?
Several other biomarkers have been investigated in HCC. Some 
have been reported as prognostic biomarkers, possibly related to 
a stem cell phenotype. For some of these markers, osteopontin is 
an example, further studies failed to confirm the prognostic role 
at tissue level; for others, like CK19, data on tissue expression 
are robust but their use in the daily practice has never been 
endorsed by international guidelines. Other markers have been 
suggested as able to discriminate patients eligible to a certain 
treatment (predictive markers). Among these, VEGF and CAIX 
have been described as possible predictive tissue biomarkers of 
TACE resistance (27). More recently, the evaluation of c-MET at 
tissue level has been related to the response to Tivantinib (28) 
while the use of Nivolumab turned out to be not predictable 
by PDL1 at tissue level (29).
These frustrating results should not discourage the study 
of novel biomarkers and their translation at tissue level into 
prognostic and predictive indicators. In the meanwhile, the best 
FiGURe 3 | Algorithmic approach to the use of tissue biomarkers in the clinical setting of small hepatocellular nodules detected in cirrhotic patients 
under surveillance and in hepatocellular nodules detected in unremarkable liver.
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approach seems that suggested by Tsujikawa et  al. (30): to use 
all the available tissue markers to separate HCC into subgroups 
reflecting tumor aggressiveness. This approach, in line with the 
work done with breast cancer, can be extremely useful in the daily 
practice.
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